LHP brings together the multidisciplinary wealth of expertise in anti-infective research and is well-positioned to adopt a one health approach for the region.


  • Infection can affect any area of the body from the lungs (pneumonia) to the brain, nervous system (meningitis or encephalitis), bones (osteomyelitis) and bladder, urethra or kidneys (urinary tract infection or UTI).
  • Infection can spread through the blood to other parts of the body, causing inflammation and have damaging consequences.
  • We estimate that in Liverpool, there have been just over 85,000 admissions to our hospitals as a result of serious infection since 2013.
  • In the UK, pneumonia affects 0.5-1% of adults each year and is usually caused by a bacterial infection.  It is more common and can be more serious in certain groups of people.
  • People with other health conditions, such as asthma, cystic fibrosis, heart, liver or kidney problems, in addition to those having chemotherapy, are at increased risk of developing pneumonia.
  • Anyone with an infection may develop sepsis.  Some people are more likely to have an infection leading to sepsis, including people with a weakened immune system, such as those having chemotherapy.  Sepsis is treated with antibiotics.
  • As antibiotic resistance poses a significant threat to the delivery of healthcare, it is essential to ensure that principles of good antimicrobial stewardship and appropriate use of antibiotics are built into all activities, communication, training and actions relating to the treatment of sepsis.
  • Infection prevention and control (IPC) is a practical evidence-based approach to prevent harm to patients and health care workers, which includes practising hand hygiene, maintaining a clean environment, monitoring infection and acting to reduce its frequency, in addition to using antibiotics only when they are truly needed, to reduce the risk of resistance.
  • Antimicrobials are fundamental components of our health system and antimicrobial resistance (AMR) strikes the poor hardest.
  • The burden of AMR is wider than the health of the individual, their family and the wellbeing of their local community: treatment of resistant infections is expensive. The cost of AMR is predicted to be £78.7 trillion globally by 2050, driving an additional 28 million people into poverty.


  • The scale of the problem, which is recognised by the UK Government in its plans to address AMR and the NHS Long Term Plan, combined with our academic strength in Liverpool, makes infection a priority for Liverpool Health Partners.
  • Prevention, detection and appropriate treatment of infection can help patients lead healthier lives for longer.
  • The potential benefits to society of discoveries and advancement in anti-infective research is huge in terms of health and wealth.
  • One of our objectives is to support a successful NIHR Biomedical Research Centre (BRC) application in 2021. Liverpool’s 2021 submission will reflect the universal, multidisciplinary perspective of the Universities and NHS in Liverpool, focussing on its academic strength and demonstrated track record of excellence and achievement, to address the health of the local, regional and national populations, using team-based problem solving.
  • Our Infection Team will work in close partnership with our Living Well colleagues to ensure we collaborate, discover and improve across the region with our partners.

The Infection Programme Team is supporting academic and NHS colleagues in providing monthly updates on work at pace and scale across the system in response to the COVID 19 pandemic, to align research strategy and performance.

A series of webinars is planned to report on the work of the STrategic One Liverpool Partnership for COVID (STOP COVID), which is supported by UoL/ LSTM Centre of Excellence in Infectious Diseases Research (CEIDR), Clinical Research Network North West Coast and the NIHR Health Protection Unit. Those participating in the first webinar heard how LHP members have invested over £1.1M into COVID19 research, recruited over 2,000 patients to associated studies and driven downtime to set up research to under a week. It was also reported that the STOP COVID initiative has enabled volunteers to support COVID19 research, developed a research platform to support projects specifically aimed at our healthcare staff and has supported new research ideas being developed across the partnership.

For more information on future webinars, contact Elizabeth Collins via

Sign up for our newsletter

If you would like to receive quarterly newsletters from Liverpool Health Partners please sign up here. We won’t use your details for any other purpose, and we won’t pass them on to any other organisation.